New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
12:25 EDTBMY, BMY, BMY, EXEL, EXEL, EXEL, JNJ, JNJ, JNJ, MDVN, MDVN, MDVN, MRK, MRK, MRK, OGXI, OGXI, OGXI, RHHBY, RHHBY, RHHBYLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide updates on GU cancer, in conjunction with the upcoming ASCO Annual Meeting where relevant companies BMY, EXEL, JNJ, MDVN, MRK, OGXI and RHHBY may be discussed on the Analyst/Industry conference call to be held on May 22 at 1 pm.
News For BMY;EXEL;JNJ;MDVN;MRK;OGXI;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 20, 2015
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
07:23 EDTMRKMerck funding testing of lower dosages of Zilmax, Reuters reports
Subscribe for More Information
January 16, 2015
16:36 EDTRHHBYMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
16:29 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
13:01 EDTJNJEarnings Preview: Johnson & Johnson reports after recent Goldman downgrade
Subscribe for More Information
12:43 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
08:58 EDTJNJRoth Capital says Depomed now leading pain company, ups to Buy
Roth Capital upgraded Depomed (DEPO) to Buy from Neutral saying the Nucynta transaction transforms the company into a "leading pain company now with critical mass." Roth raised its price target for shares to $25. Depomed last night announced that it acquired the U.S. rights to the Nucyntafranchise for $1.05B from Johnson & Johnson's (JNJ) Jansen unit. Depomed is trading up 9% in pre-market trading to $19.19.
08:12 EDTJNJJohnson & Johnson forms Ebola vaccine development consortia
Subscribe for More Information
06:32 EDTOGXIOncoGenex reports Phase 3 AFFINITY trial continuing as planned
Subscribe for More Information
06:32 EDTOGXIOncoGenex says AFFINITY trial expected to continue as planned
Subscribe for More Information
06:21 EDTRHHBYRoche acquires Trophos for EUR120M plus contingent payments
Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime, TRO19622, which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a pivotal phase II clinical trial with olesoxime in SMA showed a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as a reduction in medical complications associated with the disease. These data were first presented in April 2014 at the annual meeting of the American Academy of Neurology. Under the terms of the agreement, Trophos’s shareholders will receive an upfront cash payment of EUR 120M, plus additional contingent payments of up to EUR 350M based on achievement of certain predetermined milestones.
January 15, 2015
16:08 EDTJNJJ&J unit sells U.S. Nucynta license rights to Depomed for $1.05B
Subscribe for More Information
16:08 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
Subscribe for More Information
16:05 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
12:10 EDTJNJJohnson & Johnson volatility elevated into Q4 and outlook
Johnson & Johnson January weekly call option implied volatility is at 22, February is at 16, April is at 15; compared to its 26-week average of 15 according to Track Data, suggesting large movement into the expected release of Q4 results on January 20.
11:20 EDTJNJ, MDVN, MRKGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTJNJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Campus (ACC) downgraded to Sell from Neutral at Goldman... Apple (AAPL) downgraded to Neutral from Buy at Mizuho... Archer Daniels (ADM) downgraded to Neutral from Buy at Goldman... Barrick Gold (ABX) downgraded to Underweight from Equal Weight at Barclays... CNOOC (CEO) downgraded to Underperform from Hold at Jefferies... CSC (CSC) downgraded to Underweight from Neutral at JPMorgan... Computer Programs (CPSI) downgraded to Market Perform from Outperform at William Blair... D.R. Horton (DHI) downgraded to Neutral from Buy at UBS... DDR Corp. (DDR) downgraded to Neutral from Overweight at JPMorgan... Dominion Diamond (DDC) downgraded to Equal Weight from Overweight at Barclays... EVERTEC (EVTC) downgraded to Neutral from Overweight at JPMorgan... Education Realty (EDR) downgraded to Sell from Neutral at Goldman... Franco-Nevada (FNV) downgraded to Underweight from Equal Weight at Barclays... General Cable (BGC) downgraded to Neutral from Buy at Longbow... Green Dot (GDOT) downgraded to Neutral from Overweight at JPMorgan... Greif (GEF) downgraded to Neutral from Buy at BofA/Merrill... Grupo Simec (SIM) downgraded to Neutral from Buy at Goldman... Hecla Mining (HL) downgraded to Hold from Buy at BB&T... Host Hotels (HST) downgraded to Hold from Buy at MLV & Co.... Ingredion (INGR) downgraded to Sell from Neutral at Goldman... Insulet (PODD) downgraded to Market Perform from Outperform at Raymond James... Johnson & Johnson (JNJ) downgraded to Sell from Neutral at Goldman... Magna (MGA) downgraded to Hold from Buy at TD Securities... Molson Coors (TAP) downgraded to Neutral from Buy at Goldman... Nuverra Environmental (NES) downgraded at Roth Capital... Omnicom (OMC) downgraded to Hold from Buy at Evercore ISI... PetroChina (PTR) downgraded to Underperform from Hold at Jefferies... Philip Morris (PM) downgraded to Sell from Neutral at Goldman... Precision Castparts (PCP) downgraded to Hold from Buy at KeyBanc... Rio Tinto (RIO) downgraded to Neutral from Outperform at Macquarie... STAG Industrial (STAG) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Equal Weight from Overweight at Barclays... Sinopec (SNP) downgraded to Underperform from Hold at Jefferies... Sky (SKYAY) downgraded to Neutral from Outperform at Exane BNP Paribas... Teledyne (TDY) downgraded to Underweight from Hold at KeyBanc... Woodward (WWD) downgraded to Underweight from Hold at KeyBanc... Xilinx (XLNX) downgraded to Equal Weight from Overweight at Barclays.
07:59 EDTMRKAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:06 EDTJNJJohnson & Johnson downgraded at Goldman
Subscribe for More Information
06:44 EDTJNJJohnson & Johnson downgraded to Sell from Neutral at Goldman
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use